K. Kolba

Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.

D. Furst, R. Fleischmann, M. Greenwald, 2002, The Journal of rheumatology.

Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study.

J. Kremer, Q. Mekki, W. Wisemandle, 2003, Arthritis and rheumatism.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

Treatment of hemophilic arthritis with D‐penicillamine: A preliminary report

J. Trombley, J. Corrigan, E. Gall, 1985, American journal of hematology.

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Jeffrey R Curtis, Maxime Dougados, Claire Bombardier, 2012, Arthritis care & research.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.

Choosing Wisely: The American College of Rheumatology's Top 5 for Pediatric Rheumatology

P. Ferguson, P. Nigrovic, A. Huttenlocher, 2014, Arthritis care & research.